PRECISION
WHERE IT MATTERS.

performance in acne treatment.1

Give your patients acne relief with AKLIEF® (trifarotene) Cream, 0.005%, an innovative and effective facial and truncal acne vulgaris prescription treatment.1 

LEARN ABOUT AKLIEF CREAM

AKLIEF Cream contains the retinoid molecule trifarotene, which specifically targets RAR-γ, the most common retinoic acid receptor in the skin. The exact process by which trifarotene ameliorates acne is unknown.1

Not an actual patient.

Male with basketball & female with tennis racket portray patients using AKLIEF® (trifarotene) Cream acne vulgaris medication

Acne Vulgaris Patient ProfilesGET TO KNOW 2 DIFFERENT PATIENT TYPES.

Read Patient Profiles

PROVEN EFFICACY IN TREATING
ACNE VULGARIS IN

2,000+

PATIENTS ENROLLED IN 2 AKLIEF CREAM CLINICAL TRIALS2

IMPROVEMENT IN BOTH FACIAL AND TRUNCAL ACNE.2

View clinical data

16 year old teen female face acne photo before AKLIEF® (trifarotene) Cream prescription acne treatment
16 year old teen female face acne photo after AKLIEF® (trifarotene) Cream prescription acne treatment

IGA=Investigator's Global Assessment.

because clearer skin matters.

PIVOTAL STUDIES 1 & 2

These studies were the first large-scale, randomized, Phase 3 clinical trials to simultaneously evaluate a topical therapy for the treatment of both moderate facial and truncal acne vulgaris.1,2

Study 18251: Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of trifarotene cream vs vehicle cream.

Subject: 8511-004 | Age: 16 | Gender: Female

SEE ALL RESULTS

Female swimmer in start position portrays confident patient after treatment of acne vulgaris with AKLIEF® (trifarotene) Cream

HELP YOUR PATIENTS SAVE ON THIS INNOVATIVE ACNE TREATMENT.*

patient savings card

*The Galderma® CAREConnect™ Program (“Program”) is brought to you by Galderma Laboratories, L.P. (“Galderma”). The Program is only available for commercially unrestricted or commercially restricted/cash paying patients at participating pharmacies. Patients who are enrolled in state or federally government-run or government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect Patient Savings Card (“Card”). Any claim under the Program must be submitted by participating pharmacies to one of the Administrators of the Program.

References: 1. AKLIEF Press Release. Federal Drug Administration approval, 2019. 2. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.

up